Foundayo (Orforglipron) Cost Without Insurance, Label & Price (2026)

Foundayo Orforglipron FDA Approval Status 2026: What Is It?

Foundayo is Eli Lilly’s once-daily oral non-peptide GLP-1 receptor agonist, now FDA-approved for chronic weight management. The brand name Foundayo applies to the obesity indication; the active ingredient is orforglipron. Foundayo is approved by the Food and Drug Administration (FDA) for adults with obesity or overweight and at least one weight-related medical problem or weight-related comorbid condition, specifically targeting excess body weight. For the direct yes-or-no answer and the exact approval date, see the canonical orforglipron approval status page.

The structural distinction matters. Unlike every other GLP-1 drug on the market — including oral semaglutide (Rybelsus) and injectable Wegovy — orforglipron is a small molecule, not a peptide. This means it does not require the absorption-enhancing formulation that forces peptide-based oral GLP-1 drugs to impose fasting conditions, limited water, and 30-minute waiting periods before eating.

Foundayo can be taken at any time of day, with or without food, with no water restrictions. For patients who have avoided GLP-1 therapy because of injection barriers or dosing complexity, this eliminates both. Foundayo is intended to be used alongside a reduced calorie diet and increased physical activity.

This was also a regulatory milestone. Foundayo became the first New Molecular Entity (NME) approved under the FDA’s Commissioner’s National Priority Voucher (CNPV) pilot program, and the fastest NME approval since 2002 — issued just 50 days after filing, a full 294 days before its PDUFA target date of January 20, 2027. As with all new FDA approvals, Foundayo carries a boxed warning and a detailed safety profile; patients should consult a healthcare provider before starting treatment. For a full view of how this sits in the pipeline, see the oral obesity drugs 2026 comparison.

ATTAIN-1 Trial: Primary Weight Loss and Obesity Data

ATTAIN-1 was the pivotal Phase 3 double-blind placebo-controlled trial that supported the FDA obesity approval. In this study, randomized participants with obesity or overweight and at least one weight-related comorbidity were assigned to receive orforglipron across three dose tiers or to a placebo group, over 72 weeks. For the broader 2026 oral obesity-drug context, see the oral obesity drugs 2026 overview.

Orforglipron achieved significant reductions in body weight compared to the placebo group, with the primary goal to reduce excess body weight and maintain weight reduction long term. The trial assessed treatment response and the ability to maintain weight reduction long term as key endpoints.

The 12.4% weight loss at the highest dose is lower than the figures seen with injectable tirzepatide (20–22%) or injectable semaglutide (15–17%). Eli Lilly CEO David Ricks has acknowledged this directly, positioning Foundayo as a more accessible option rather than the most potent one. The value proposition is oral convenience, not maximum efficacy. For how this stacks up against the still-investigational triple-agonist, see retatrutide vs orforglipron.

ACHIEVE-3: Head-to-Head vs Oral Semaglutide

ACHIEVE-3 was a pivotal randomized double blind placebo-controlled head-to-head trial comparing orforglipron directly against oral semaglutide in 1,698 participants with type 2 diabetes over 52 weeks. This is the only blinded, controlled comparison between the two oral GLP-1 drugs. For the deeper Rybelsus background, see our oral semaglutide (Rybelsus) guide.

When orforglipron compared to oral semaglutide, orforglipron outperformed on both the primary and all key secondary endpoints. The 73.6% greater relative weight loss is significant. However, the discontinuation rate due to adverse events was roughly double that of oral semaglutide — a tolerability trade-off that is important context for the efficacy numbers.

ATTAIN-MAINTAIN: Switching from Injectables

One of the most clinically relevant questions: can patients switch from injectable GLP-1 drugs to an oral option without losing their progress? The ATTAIN-MAINTAIN study addressed this directly.

• From injectable semaglutide to orforglipron: Participants maintained their weight loss, with an average difference of only 0.9 kg — essentially weight-neutral.
• From tirzepatide to orforglipron: Weight was maintained with an average difference of 5 kg — a larger gap, reflecting tirzepatide’s dual-agonist mechanism producing greater initial weight loss.

This data positions Foundayo as a viable oral maintenance option for patients who achieve initial weight loss on injectables but want to transition to a pill. The injectable-to-oral pathway could become a standard clinical strategy.

Foundayo vs Injectable GLP-1s: Full Comparison

The GLP-1 landscape now spans four FDA-approved options (plus investigational compounds). Here is how Foundayo fits against the field.

*Retatrutide Phase 3 readouts published: TRIUMPH-4 (December 2025, 28.7% weight loss at 12 mg, 68 weeks) and TRANSCEND-T2D-1 (March 2026). Retatrutide is not FDA-approved and is available only as a research compound. See retatrutide approval status.

Foundayo Pricing and Availability

Eli Lilly has launched Foundayo with a tiered pricing structure designed to undercut the existing GLP-1 market on cost, with pricing varying by dose tier and starting dosage.

Analyst forecasts suggest that Foundayo’s competitive pricing and broad availability are expected to drive significant real-world use, improving patient access and adherence outside of clinical trials.

Availability Timeline

• April 1, 2026: FDA approval granted. Prescriptions accepted via LillyDirect immediately.
• April 6, 2026: Free home delivery shipping begins via LillyDirect.
• Shortly after: Broad availability through U.S. retail pharmacies and telehealth providers.
• July 1, 2026: Medicare Part D coverage at $50/month expected to begin.

Analysts have forecast more than 5 million Foundayo prescriptions in 2026 alone. The Emirates Drug Establishment (EDE) approved Foundayo on April 3, 2026 — 48 hours after the FDA — with patient availability in the UAE from May 2026. EU, UK, and other GCC approvals have not been announced yet. For current UAE GLP-1 availability, see GLP-1 medications in the UAE.

Side Effect Profile

Gastrointestinal adverse events are the primary tolerability concern with Foundayo, consistent with all GLP-1 receptor agonists.

• GI adverse events: Occurred in 60–69% of Foundayo-treated patients across the ATTAIN program, compared to 37% on placebo.
• Most common: Nausea, diarrhea, vomiting, dyspepsia, decreased appetite, constipation, and abdominal pain.
• Discontinuation due to GI: 3–6% depending on dose (vs 0.7% placebo).
• Timing: GI symptoms were most common during dose escalation and decreased over time on stable doses.
• Other potential side effects: Hair loss has also been reported.

Serious adverse events reported in clinical trials or post-marketing surveillance include acute kidney injury, acute gallbladder disease, and volume depletion. There is a boxed warning for thyroid c-cell tumors based on rodent studies. Rare but serious risks include gastroesophageal reflux disease, deep sedation, general anesthesia, pulmonary aspiration, and diabetic retinopathy.

In comparative analysis, orforglipron had roughly 4x higher odds of discontinuation due to adverse events and approximately 14x higher odds of GI-related discontinuation compared to oral semaglutide. This tolerability gap is an important consideration alongside the efficacy advantage shown in ACHIEVE-3. For broader side effect context across the GLP-1 class, see GLP-1 side effects comparison.

Secondary outcomes in clinical trials also showed improvements in cardiometabolic risk markers such as waist circumference, non-HDL cholesterol, triglycerides, and blood pressure.

What Foundayo Means for the GLP-1 Receptor Agonist Landscape

Foundayo’s approval reshapes the GLP-1 market in three ways:

1. Accessibility expansion. Fewer than 1 in 10 people who could benefit from a GLP-1 are currently taking one. The primary barriers are needle aversion, dosing complexity, and cost. Foundayo removes the first two. Eli Lilly’s pricing strategy addresses the third. A $25/month pill with no dosing restrictions lowers every barrier simultaneously.

2. Lilly’s dual-option portfolio. Eli Lilly now offers both Zepbound (injectable tirzepatide, 20–22% weight loss) for maximum efficacy and Foundayo (oral orforglipron, 12.4% weight loss) for maximum convenience. This covers the full spectrum — patients who want the strongest option and patients who want the easiest option.

3. The Novo Nordisk competition. Novo Nordisk launched Oral Wegovy (oral semaglutide) in December 2025, giving them a three-month head start. But Foundayo’s no-food/no-water restriction is a meaningful practical advantage. The market will sort this out quickly based on real-world adherence data.

Looking ahead: The next frontier in this space is multi-pathway agonism. Retatrutide, Eli Lilly’s investigational triple-agonist (GLP-1 + GIP + glucagon), showed 24.2% weight loss in Phase 2 — nearly double Foundayo’s figure. Phase 3 trials (the TRIUMPH program) are ongoing. For researchers tracking the full pipeline, see the 2026 obesity drug approval tracker.